$BMRA
BIOMERICA INC Stock $bmra

$bmra Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000149315224034208 Filed on August 28, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$1.807M	$1.116M	$5.415M
YoY Change	5.49%	0.7%	1.42%
Cost Of Revenue	$1.518M	$1.096M	$4.804M
YoY Change	16.68%	1.54%	-1.82%
Gross Profit	$289.0K	$20.00K	$611.0K
YoY Change	-29.85%	-30.58%	37.0%
Gross Profit Margin	15.99%	1.79%	11.28%
Selling, General & Admin	$1.360M	$1.283M	$5.487M
YoY Change	16.04%	-14.22%	-9.83%
% of Gross Profit	470.59%	6415.0%	898.04%
Research & Development	$297.0K	$265.0K	$1.491M
YoY Change	-37.08%	-28.16%	-5.87%
% of Gross Profit	102.77%	1325.0%	244.03%
Depreciation & Amortization	$21.00K	$22.00K	$81.00K
YoY Change	0.0%	19.83%	-3.57%
% of Gross Profit	7.27%	110.0%	13.26%
Operating Expenses	$1.657M	$1.548M	$6.978M
YoY Change	0.79%	-16.98%	-9.01%
Operating Profit	-$1.368M	-$1.528M	-$6.367M
YoY Change	11.04%	-16.77%	-11.85%
Interest Expense	$56.00K	$114.0K	$431.0K
YoY Change	-53.33%	104.93%	224.06%
% of Operating Profit
Other Income/Expense, Net	$56.00K		$431.0K
YoY Change	-54.47%		221.64%
Pretax Income	-$1.312M	-$1.414M	-$5.936M
YoY Change	18.3%	-20.52%	-16.26%
Income Tax	$4.000K	$7.000K	$42.00K
% Of Pretax Income
Net Earnings	-$1.316M	-$1.421M	-$5.978M
YoY Change	16.25%	-20.71%	-16.27%
Net Earnings / Revenue	-72.83%	-127.33%	-110.4%
Basic Earnings Per Share	-$0.08		-$0.36
Diluted Earnings Per Share	-$0.08	-$0.08	-$0.36
COMMON SHARES
Basic Shares Outstanding	16.82M shares	16.82M shares	16.82M shares
Diluted Shares Outstanding	16.82M shares		16.82M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.820M	$4.170M	$4.170M
YoY Change	-64.71%	-57.09%	-57.09%
Cash & Equivalents	$2.820M	$4.170M	$4.170M
Short-Term Investments
Other Short-Term Assets	$132.0K	$238.0K	$238.0K
YoY Change	-52.86%	-20.67%	-20.67%
Inventory	$1.942M	$2.376M	$2.376M
Prepaid Expenses
Receivables	$1.551M	$947.0K	$947.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.445M	$7.731M	$7.731M
YoY Change	-44.31%	-39.59%	-39.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$184.0K	$201.0K	$943.0K
YoY Change	-15.6%	-5.63%	-24.44%
Goodwill
YoY Change
Intangibles	$207.0K	$212.0K
YoY Change	2.48%	28.48%
Long-Term Investments	$165.0K	$165.0K	$165.0K
YoY Change	-2.94%	0.0%	0.0%
Other Assets	$203.0K	$203.0K	$203.0K
YoY Change	111.46%	156.96%	156.96%
Total Long-Term Assets	$1.425M	$1.523M	$1.523M
YoY Change	-13.37%	-8.09%	-8.09%
TOTAL ASSETS
Total Short-Term Assets	$6.445M	$7.731M	$7.731M
Total Long-Term Assets	$1.425M	$1.523M	$1.523M
Total Assets	$7.870M	$9.254M	$9.254M
YoY Change	-40.46%	-35.98%	-35.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.089M	$288.0K	$288.0K
YoY Change	53.38%	-16.28%	-16.28%
Accrued Expenses	$977.0K	$850.0K	$1.831M
YoY Change	0.72%	55.11%	18.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.151M	$2.204M	$2.204M
YoY Change	23.2%	13.32%	13.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$373.0K	$459.0K	$459.0K
YoY Change	-47.46%	-41.53%	-41.53%
Total Long-Term Liabilities	$373.0K	$459.0K	$459.0K
YoY Change	-47.46%	-41.53%	-41.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.151M	$2.204M	$2.204M
Total Long-Term Liabilities	$373.0K	$459.0K	$459.0K
Total Liabilities	$2.524M	$2.663M	$2.663M
YoY Change	2.98%	-2.45%	-2.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.50M	-$48.00M
YoY Change	14.32%	14.29%
Common Stock	$1.346M	$1.346M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.346M	$6.591M	$6.591M
YoY Change
Total Liabilities & Shareholders Equity	$7.870M	$9.254M	$9.254M
YoY Change	-40.46%	-35.98%	-35.98%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$1.316M	-$1.421M	-$5.978M
YoY Change	16.25%	-20.71%	-16.27%
Depreciation, Depletion And Amortization	$21.00K	$22.00K	$81.00K
YoY Change	0.0%	19.83%	-3.57%
Cash From Operating Activities	-$1.344M	-$1.044M	-$5.361M
YoY Change	-19.71%	8.45%	-2.06%
INVESTING ACTIVITIES
Capital Expenditures		$24.00K	$51.00K
YoY Change		69.73%	-20.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$24.00K	-$115.0K
YoY Change		69.73%	47.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-81.00K	-$81.00K
YoY Change		-101.1%	-100.86%
NET CHANGE
Cash From Operating Activities	-$1.344M	-1.044M	-$5.361M
Cash From Investing Activities		-24.00K	-$115.0K
Cash From Financing Activities		-81.00K	-$81.00K
Net Change In Cash	-$1.350M	-1.149M	-$5.549M
YoY Change	-22.01%	-118.03%	-245.95%
FREE CASH FLOW
Cash From Operating Activities	-$1.344M	-$1.044M	-$5.361M
Capital Expenditures		$24.00K	$51.00K
Free Cash Flow	-$1.344M	-$1.068M	-$5.412M
YoY Change	-20.71%	9.33%	-2.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000073290
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-37863
CY2024	dei	Entity Registrant Name EntityRegistrantName	BIOMERICA, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-2645573
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	17571 Von Karman Avenue
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	City Area Code CityAreaCode	949
CY2024	dei	Local Phone Number LocalPhoneNumber	645-2111
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.08
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16821646	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16821646	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16821646	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16821646	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1346000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52705000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42217000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14454000	usd
CY2023	us-gaap	Revenues Revenues	5339000	usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024	BMRA	Write Off Of Fixed Assets Cost WriteOffOfFixedAssetsCost		usd
CY2024	BMRA	Write Off Of Fixed Assets Accumulated Depreciation WriteOffOfFixedAssetsAccumulatedDepreciation		usd
CY2024	BMRA	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost		usd
CY2024	BMRA	Write Off Of Intangible Assets Accumulated Amortization WriteOffOfIntangibleAssetsAccumulatedAmortization		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount		usd
CY2023Q2	BMRA	Deferred Tax Assets Losses Of Foreign Subsidiaries Other Net DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet		usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-05-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2024	dei	Trading Symbol TradingSymbol	BMRA
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	14544346	usd
CY2024	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.08
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16821646	shares
CY2024	dei	Auditor Firm AuditorFirmId	200
CY2024	dei	Auditor Name AuditorName	HASKELL & WHITE LLP
CY2024	dei	Auditor Location AuditorLocation	Irvine, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4170000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9719000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	947000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	722000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2376000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2056000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	238000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	7731000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	12797000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213000	usd
CY2024Q2	BMRA	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	910000	usd
CY2023Q2	BMRA	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	617000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	742000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1035000	usd
CY2024Q2	us-gaap	Investments Investments	165000	usd
CY2023Q2	us-gaap	Investments Investments	165000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	48000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	30000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	212000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	165000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	203000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79000	usd
CY2024Q2	us-gaap	Assets Assets	9254000	usd
CY2023Q2	us-gaap	Assets Assets	14454000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1138000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	892000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	655000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	696000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	85000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	60000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	326000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2204000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1945000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	459000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	785000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2663000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2730000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4428571	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4428571	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-110000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	4893000	usd
CY2023	us-gaap	Gross Profit GrossProfit	446000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6085000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1584000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	7669000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7223000	usd
CY2023	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	133000	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1000	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	431000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	134000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5936000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7089000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5978000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7140000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16821646	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14154269	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16821646	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14154269	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5978000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7140000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	8000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-36000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5970000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7176000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8325000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1961000	usd
CY2023	BMRA	Stock Issued During Period Value Shares Issued In Connection With Public Offering StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOffering	7348000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-36000	usd
CY2023	BMRA	Adjustments To Additional Paid In Capital Compensation Expense In Connection With Options Granted AdjustmentsToAdditionalPaidInCapitalCompensationExpenseInConnectionWithOptionsGranted	1185000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7140000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	8000	usd
CY2024	BMRA	Adjustments To Additional Paid In Capital Compensation Expense In Connection With Options Granted AdjustmentsToAdditionalPaidInCapitalCompensationExpenseInConnectionWithOptionsGranted	837000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5978000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6591000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6591000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-5978000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7140000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	81000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-10000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	342000	usd
CY2024	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-205000	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-174000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	837000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1185000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	293000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	267000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	215000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	291000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	115000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-534000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-18000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	246000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-80000	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-41000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	49000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	25000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-297000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-297000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5361000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5474000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	64000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10014000	usd
CY2024	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	81000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	705000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-81000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9390000	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5549000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3802000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9719000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5917000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4170000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9719000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	41000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51000	usd
CY2023	BMRA	Write Off Of Fixed Assets Cost WriteOffOfFixedAssetsCost	40000	usd
CY2023	BMRA	Write Off Of Fixed Assets Accumulated Depreciation WriteOffOfFixedAssetsAccumulatedDepreciation	40000	usd
CY2023	BMRA	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost	6000	usd
CY2023	BMRA	Write Off Of Intangible Assets Accumulated Amortization WriteOffOfIntangibleAssetsAccumulatedAmortization	6000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zASloOkR9sZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zSJ8TJCoeNi4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTING ESTIMATES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities at the date of the financial statements. These estimates also impact the reported amounts of revenues and expenses during the reporting period. Key estimates include the allowance for doubtful accounts, based on both current and historical practices with customers; variable consideration in revenue recognition, estimated based on agreements that include guarantees of specified profit margins, requiring adjustments based on actual sales performance and market conditions, stock option forfeiture rates, calculated using historical data; and inventory obsolescence, where inventory is stated at the lower of cost or net realizable value (NRV) and assessed through judgments based on projected and historical usage of materials. The valuation of lease liabilities and right-of-use assets also involves assumptions such as the borrowing rate at lease commencement and the likelihood of lease extensions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These estimates are critical to our financial reporting, and actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48000000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4170000	usd
CY2024Q2	BMRA	Working Capital WorkingCapital	-5527000	usd
CY2021Q1	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	15000000	usd
CY2023Q3	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	20000000	usd
CY2024Q2	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	5500000	usd
CY2024Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	81000	usd
CY2024	BMRA	Average Trading Volume Description AverageTradingVolumeDescription	The average trading volume of our stock over the last three full calendar months is approximately 229,000 shares per day and the high and low trading price of our stock during the same period of time was $1.25 and $0.50, respectively.
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4170000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9719000	usd
CY2024Q2	BMRA	Working Capital WorkingCapital	-5527000	usd
CY2023Q2	BMRA	Working Capital WorkingCapital	10852000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zXmQs5wolAwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zcidVbRKUuq5">CONCENTRATION OF CREDIT RISK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time, the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our net sales were approximately $<span id="xdx_909_eus-gaap--Revenues_c20230601__20240531_znCMpWNVGtAe">5,415,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for fiscal 2024, compared to $<span id="xdx_90D_eus-gaap--Revenues_c20220601__20230531_zHqcwJiHzZvh">5,339,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for fiscal 2023. For the fiscal years ended May 31, 2024, and 2023, the Company had one distributor each year that accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20240531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zz86YJWXbyoa">33</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorOneMember_zfEYPdhRixvc">35</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of our net sales, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total gross receivables as of May 31, 2024, and 2023 were approximately $<span id="xdx_906_eus-gaap--OtherReceivablesGrossCurrent_iI_c20240531_zIrkOrXXf6T3" title="Other receivables, gross, current">966,000</span> and $<span id="xdx_907_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zUskxGsR9AU4" title="Other receivables, gross, current">751,000</span>, respectively. As of May 31, 2024, and 2023, the Company had four and one distributor, respectively, that accounted for a total of <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20240531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDistributorMember_zM1AJ04EJgnf" title="Concentration risk, percentage">64</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneDistributorMember_zKWARtDmL41c" title="Concentration risk, percentage">36</span>% of gross accounts receivable. Of the <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20240531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDistributorMember_zNuqktN4Jbzh" title="Concentration risk, percentage">64</span>% as of May 31, 2024, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorsInAsiaMember_zraHaQc8jD6a" title="Concentration risk, percentage">37</span>% was owed by a distributor in Asia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the fiscal year ended May 31, 2024, the Company had one vendor which accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20240531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zmOqdcD3YNC9" title="Concentration risk, percentage">16</span>% of the purchases of raw materials. For the fiscal year ended May 31, 2023, the Company did not have any significant concentration of vendor spend for raw materials.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024	us-gaap	Revenues Revenues	5415000	usd
CY2023	us-gaap	Revenues Revenues	5339000	usd
CY2024Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	966000	usd
CY2023Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	751000	usd
CY2024	us-gaap	Threshold Period Past Due For Writeoff Of Trade Accounts Receivable ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable	P90D
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	19000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	29000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	238000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	300000	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1519000	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1677000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1145000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	869000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	179000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	182000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	2843000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	2728000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	467000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	672000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2376000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2056000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	467000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	672000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2024	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	837000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1185000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0054	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1198	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9881	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0177	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.040	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0459	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0312	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0335	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2024	us-gaap	Proceeds From Customers ProceedsFromCustomers	85000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5415000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5339000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1491000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1584000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10369000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10369000	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	101000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	156000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1394000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1331000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213000	usd
CY2024Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	260000	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	196000	usd
CY2024Q2	BMRA	Finite Lived Patents Accumulated Amortization FiniteLivedPatentsAccumulatedAmortization	48000	usd
CY2023Q2	BMRA	Finite Lived Patents Accumulated Amortization FiniteLivedPatentsAccumulatedAmortization	31000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	212000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	165000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	122000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	212000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	288000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	344000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	850000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	548000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1138000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	892000	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	837000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1185000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2321616	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.72
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1838000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	243000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.70
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	90000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	175500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.56
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2342616	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.52
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	146000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1338500	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.13
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	201500	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.64
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3479616	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.53
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2047712	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.23
CY2023Q1	BMRA	Sale Of Stock Expenses SaleOfStockExpenses	700000	usd
CY2023Q3	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	20000000	usd
CY2024Q2	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	5500000	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-41000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-50000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1000	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-42000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-51000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1247000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1490000	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1428000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1973000	usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	459000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	583000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-148000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-17000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-5000	usd
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-172000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-129000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	5000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	8000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	131000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	188000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	144000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	118000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6658000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5817000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1380000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1239000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	11000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	11000	usd
CY2024Q2	BMRA	Deffered Tax Assets Stock Options DefferedTaxAssetsStockOptions	1561000	usd
CY2023Q2	BMRA	Deffered Tax Assets Stock Options DefferedTaxAssetsStockOptions	1296000	usd
CY2024Q2	BMRA	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	501000	usd
CY2023Q2	BMRA	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	284000	usd
CY2024Q2	BMRA	Deferred Tax Assets Losses Of Foreign Subsidiaries Other Net DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet	2000	usd
CY2024Q2	BMRA	Deferred Tax Assets Accumulated Depreciation And Amortization DeferredTaxAssetsAccumulatedDepreciationAndAmortization	-24000	usd
CY2023Q2	BMRA	Deferred Tax Assets Accumulated Depreciation And Amortization DeferredTaxAssetsAccumulatedDepreciationAndAmortization	-21000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10369000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8940000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10369000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8940000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10369000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8940000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1429000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1973000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024	us-gaap	Revenues Revenues	5415000	usd
CY2023	us-gaap	Revenues Revenues	5339000	usd
CY2024Q2	us-gaap	Area Of Land AreaOfLand	22000	sqft
CY2016Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in the Company’s manufacturing process
CY2016Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2023Q2	us-gaap	Area Of Land AreaOfLand	8100	sqft
CY2016Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	11000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	14000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	5000	usd
CY2024	us-gaap	Lease Cost LeaseCost	378000	usd
CY2023	us-gaap	Lease Cost LeaseCost	358000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	365000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	376000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	101000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	842000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	57000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	785000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	356000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	347000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M7D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M7D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure

Files In Submission

Name	View Source	Status
0001493152-24-034208-index-headers.html	Edgar Link	pending
0001493152-24-034208-index.html	Edgar Link	pending
0001493152-24-034208.txt	Edgar Link	pending
0001493152-24-034208-xbrl.zip	Edgar Link	pending
bmra-20240531.xsd	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
bmra-20240531_def.xml	Edgar Link	unprocessable
bmra-20240531_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmra-20240531_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bmra-20240531_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRA
BIOMERICA INC Stock $bmra

2024 Q3 Form 10-K Financial Statement

#000149315224034208 Filed on August 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA BIOMERICA INC Stock $bmra

2024 Q3 Form 10-K Financial Statement

#000149315224034208 Filed on August 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA
BIOMERICA INC Stock $bmra